BFRG

GAITHERSBURG, Md., June 02, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence ("AI") and machine learning to turn complex biomedical data into actionable insights, today announced it has appointed commercial technology sales and scientific-focused leaders to support the momentum of the Company's commercial business driven growth strategy. The new commercial management team brings combined expertise in scaling enterprise technology, implementing go-to-market strategic initiatives across global markets, driving and scaling revenue, and advancing target identification, discovery, and c

S-1 - BullFrog AI Holdings, Inc. (0001829247) (Filer)

10-Q - BullFrog AI Holdings, Inc. (0001829247) (Filer)

DEFA14A - BullFrog AI Holdings, Inc. (0001829247) (Filer)

DEF 14A - BullFrog AI Holdings, Inc. (0001829247) (Filer)

8-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)

GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence ("AI") and machine learning to turn complex biomedical data into actionable insights, today announced that it has received a written notice from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company has regained compliance with the minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Rule"). On April 21, 2026, the Company received a letter from Nasdaq notifying the Company that it had regained compliance with the Stockholders' Equity Rule, whic

8-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)

GAITHERSBURG, Md., April 14, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence ("AI") and machine learning to turn complex biomedical data into actionable insights, today announced its participation as an exhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2026. The AACR Annual Meeting will be held from April 17-22 at the San Diego Convention Center in San Diego, California. Companies, researchers, and other conference attendees who are interested in meeting with the BullFrog AI team should visit booth 2957 or contact Steven Seegers at steven.seegers@bul

8-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)

GAITHERSBURG, Md., April 13, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence and machine learning to turn complex biomedical data into actionable insights, today issued the following letter to shareholders from Vin Singh, Founder and CEO: Dear Fellow Shareholders, BullFrog AI enters the second quarter of 2026 well-capitalized, at commercial stage, and in active discussions with consequential pharmaceutical and biotechnology organizations. We just closed our first agreement with a top 5 global pharmaceutical company, secured the financial runway to execute our strategy into late

424B5 - BullFrog AI Holdings, Inc. (0001829247) (Filer)

8-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)

8-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)

Commercial agreement serves as high-profile third party validation of BullFrog AI's proprietary capabilities Agreement utilizes BullFrog AI's end-to-end analytical AI platform to accelerate drug discovery and development program  GAITHERSBURG, Md., March 30, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence ("AI") and machine learning to turn complex biomedical data into actionable insights, today announced a commercial agreement with a top 5 global pharmaceutical company in 2025 by revenue ("Customer"), to apply the Company's proprietary bfLEAP® platform to identify and prioritize

GAITHERSBURG, Md., March 25, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence ("AI") and machine learning to turn complex biomedical data into actionable insights, today unveiled bfARENAS™, a new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design, bolstering its end-to-end AI intelligence workflow. The Company will host a webinar in partnership with Xtalks Life Sciences on bfARENAS™ on March 27, 2026 at 11 a.m. ET. Organizations across biotech, pharma, and clinical research operate in high-uncertainty environments where timelines are lon

10-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)

GAITHERSBURG, Md., March 11, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence ("AI") and machine learning to turn complex biomedical data into actionable insights, will host a webinar in partnership with Xtalks Life Sciences, "Turning AI Recommendations into Clear, Defensible Decisions", about BullFrog AI's new precision AI capability on Friday, March 27, 2026 at 11 a.m. ET. The new AI capability advances the Company's end-to-end intelligence workflow by adding a strategic decision support layer on top of existing platforms bfPREP™ and bfLEAP®. Unlike traditional portfolio tools t

8-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)

8-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)

New capabilities to be launched on March 25Unique technology bolsters BullFrog AI's end-to-end AI intelligence workflow with a scenario-based decision engineAdvances current AI decision tools by clearly defining clinical trial strategies and building diversified, risk-balanced R&D portfolios GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence ("AI") and machine learning to turn complex biomedical data into actionable insights, announces the coming launch of a new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design

GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence ("AI") and machine learning to turn complex biomedical data into actionable insights, publishes a white paper titled, "Data Harmonization: The Hidden Prerequisite for Reliable AI/ML in Life Sciences," with a discussion on how BullFrog AI's bfPREPTM immediately recognizes reliable patterns to transform raw biomedical data into harmonized, clinically contextualized formats, providing reliable insights and trustworthy analytical assets to assist in drug development. "The rush to apply AI in biopharma drug de

DENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Markets are opening with a clear appetite for substance over speculation, as investors gravitate toward companies delivering late-stage clinical wins, scalable science, and data-driven precision platforms. Alumis (NASDAQ:ALMS): Phase 3 Data Redefines the Oral Psoriasis Landscape Alumis is firmly in focus after announcing positive topline results from two Phase 3 trials (ONWARD1 and ONWARD2) evaluating envudeucitinib, its next-generation oral TYK2 inhibitor, in moderate-to-severe plaque psoriasis. Both trials met all primary and secondary endpoints with high statistical significance, with efficacy that stands out among oral therapies. By Week 24,

GAITHERSBURG, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence ("AI") and machine learning to turn complex biomedical data into actionable insights, highlights the presentation of data derived from the use of the Company's proprietary platform bfLEAP® with pancreatic cancer trial data to identify an almost three times increase in mean survival from the control to treatment arms. The data will be presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on Jan. 9 at poster session B. The presentation, in collaboration wit

8-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)